The murky path to drug discovery in ALS becomes clearer
- 1 November 2013
- journal article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 12 (11), 1037-1038
- https://doi.org/10.1016/s1474-4422(13)70224-2
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialThe Lancet Neurology, 2013
- The current and projected economic burden of Parkinson's disease in the United StatesMovement Disorders, 2013
- The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosisNature Medicine, 2011
- Design, power, and interpretation of studies in the standard murine model of ALSAmyotrophic Lateral Sclerosis, 2008
- Selecting promising ALS therapies in clinical trialsNeurology, 2006
- An efficient multi‐stage, single‐arm Phase II futility design for ALSAmyotrophic Lateral Sclerosis, 2004
- Dose-ranging study of riluzole in amyotrophic lateral sclerosisThe Lancet, 1996
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- The origin of "Awakenings".BMJ, 1983
- Aromatic Amino Acids and Modification of ParkinsonismNew England Journal of Medicine, 1967